Phase 2Completed

A Controlled-Study on the Effect of a Combination of Fenofibrate and Metformin on Weight Loss and Weight Loss-Maintenance, in Obese Patients.

A Double-Blind, 3-Arm Study on Weight Loss With a Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Per Day Compared to Metformin 1,700 mg and to Placebo, at 6 Months, in Obese Patients, Followed by: A Double-Blind, 2-Arm Investigation of Weight-Loss Maintenance With the Same Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Compared to Placebo, at 6 Months, in the Responders.

Sponsor
Solvay Pharmaceuticals (Industry)
Enrollment
148 planned
Conditions
Obesity
Interventions
Metformin and Metformin + Fenofibrate
Ages
adults
Registry
NCT00349635, EUCTR2004-001731-28

Full record on ClinicalTrials.gov

From the registry

To investigate the effect on body weight of a combination fenofibrate and metformin on top of a moderate balanced calorie-deficit diet.

Primary outcomes

  • Weight

History

  1. Last registry update

  2. Registered

  3. Started